Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Important treatment gaps in vascular protection for the elderly after type 2 diabetes therapy initiation.

Guénette L, Breton MC, Hamdi H, Grégoire JP, Moisan J.

Can J Cardiol. 2013 Dec;29(12):1593-8. doi: 10.1016/j.cjca.2013.09.001. Epub 2013 Oct 30.

PMID:
24183301
2.

Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.

Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J.

Am J Kidney Dis. 2005 Dec;46(6):1080-7.

PMID:
16310574
3.

Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.

Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R.

J Am Soc Nephrol. 2006 Mar;17(3):889-99. Epub 2006 Feb 15.

4.
5.

Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus.

Tjia J, Briesacher BA.

J Am Geriatr Soc. 2008 Oct;56(10):1879-86. doi: 10.1111/j.1532-5415.2008.01917.x. Epub 2008 Sep 2.

6.

Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.

Yang Y, Thumula V, Pace PF, Banahan BF 3rd, Wilkin NE, Lobb WB.

J Am Pharm Assoc (2003). 2010 Jul-Aug;50(4):527-31. doi: 10.1331/JAPhA.2010.09071.

PMID:
20621872
7.

Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.

Lamb DA, Eurich DT, McAlister FA, Tsuyuki RT, Semchuk WM, Wilson TW, Blackburn DF.

Circ Cardiovasc Qual Outcomes. 2009 May;2(3):228-35. doi: 10.1161/CIRCOUTCOMES.108.813600. Epub 2009 Apr 28.

8.

No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.

Han SW, Won YW, Yi JH, Kim HJ.

Nephrol Dial Transplant. 2007 Apr;22(4):1150-5. Epub 2007 Jan 25.

10.
12.

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

Fitchett D.

Vasc Health Risk Manag. 2009;5(1):21-9. Epub 2009 Apr 8. Review.

13.
14.

Association Between Loyalty to Community Pharmacy and Medication Persistence and Compliance, and the Use of Guidelines-Recommended Drugs in Type 2 Diabetes: A Cohort Study.

Dossa AR, Grégoire JP, Lauzier S, Guénette L, Sirois C, Moisan J.

Medicine (Baltimore). 2015 Jul;94(27):e1082. doi: 10.1097/MD.0000000000001082.

15.

Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.

Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R.

Kidney Blood Press Res. 2009;32(4):268-75. doi: 10.1159/000239765. Epub 2009 Sep 18.

PMID:
19776644
16.
17.

Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.

Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovesdy CP.

J Am Coll Cardiol. 2014 Feb 25;63(7):650-8. doi: 10.1016/j.jacc.2013.10.050. Epub 2013 Nov 21.

18.
19.

Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?

Tomaszuk-Kazberuk A, Kozuch M, Malyszko J, Bachorzewska-Gajewska H, Dobrzycki S, Musial WJ.

Ren Fail. 2013;35(2):235-42. doi: 10.3109/0886022X.2012.745119. Epub 2012 Nov 26.

PMID:
23176538
20.

Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.

Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R.

Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):55-64.

PMID:
16470693
Items per page

Supplemental Content

Write to the Help Desk